Reece Pharmaceuticals (ASX:RCE) - Executive Director, James Graham
Executive Director, James Graham
Sourced: Finance News Network
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Pharmaceuticals’s (RCE) Recce 327 antibiotic is showing promise in treating gonorrhoea, a bacteria which is increasingly antibiotic-resistant
  • Already, the bacteria has developed resistance to all but one class of antibiotics, making the search for a new treatment a global priority
  • A trial in mice tested different doses of the compound Recce 327 and compared it to Meropenem, a market approved drug
  • As the dose of Recce 327 increased the bacterial count was significantly reduced and even more so than in mice treated with Meropenem
  • Recce Pharmaceuticals closed 5.3 per cent higher at 39.5 cents each

Recce Pharmaceuticals’s (RCE) Recce 327 antibiotic is showing promise in treating gonorrhoea, a bacteria which is increasingly antibiotic-resistant.

The bacteria neisseria gonorrhoeae has developed resistance to all but one class of antibiotics and has been listed as a significant threat to human health by the World Health Organisation.

“There is an urgent need to find a new class of effective antibiotics to kill the pathogen before it develops resistance to the last recommended treatment,” said Recce Pharmaceuticals Non-Executive Chairman Dr John Prendergast.

“Data from this study, along with previous other reports, continue to highlight the potential of RECCE 327 to not only become a potent broad-spectrum antibiotic but most critically to continue working against antibiotic-resistant bacteria or superbugs, even with numerous repeated uses,” he added.

The study in mice was conducted by an independent Contract Research Organisation and was designed to test the dose-dependency of Recce 327 against neisseria gonorrhoeae.

In the trial, mice were given either a market-approved drug called Meropenem or different doses of Recce 327 twice daily for seven days, starting two days after the initial infection.

Credit: Recce Pharmaceuticals

The results showed that the extent to which Recce 327 reduced bacteria was dependent on the dose, as the study director explained.

“RECCE 327 showed a significant dose-dependent antibacterial effect in vaginal load at 100, 500 and 1000 mg/kg given by intravenous bolus when compared to the control group seven days post-infection.”

As the dose increased the bacterial count was significantly reduced and with the higher doses, even more so than in mice treated with Meropenem.

Recce Pharmaceuticals closed 5.3 per cent higher at 39.5 cents each.

RCE by the numbers
More From The Market Herald
The Market Herald Video

" Emyria (ASX:EMD) launches phase 3 EMD-RX5 trial

Emyria (ASX:EMD) has launched its phase three clinical trial of its ultra-pure CBD candidate.
The Market Herald Video

" Prescient Therapeutics (ASX:PTX) locks in OmniCAR cell manufacturing contract for clinical trials

Prescient Therapeutics (ASX:PTX) has signed a manufacturing services agreement with Q-Gen Cell Therapeutics to produce its…
The Market Herald Video

" Opthea (ASX:OPT) secures up to US$260m in funding for OPT-302 trials

Opthea (ASX:OPT) secures up to US$170 million in financing and a US$90 million placement to advance…
Creso Pharma (ASX:CPH) -

" Creso Pharma’s (ASX:CPH) ImpACTIVE appoints new brand ambassador

Creso Pharma's (ASX:CPH) subsidiary, ImpACTIVE has appointed multi-sport performance coach Kolby Tullier as brand ambassador.